New pill combo aims to boost prostate cancer cure rates

NCT ID NCT06130995

Recruiting now Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether taking two hormone-blocking pills—relugolix and enzalutamide—before and after standard radiation or surgery can help cure high-risk locally advanced prostate cancer. About 46 men will participate to first find a safe dose, then see if the combo shrinks tumors more effectively. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: relugolix and enzalutamide (hormone-blocking pills)
What this could lead to: If this combination works, it could improve the chance of curing high-risk prostate cancer and help patients live longer without the cancer returning.
What could go wrong: This is a very early Phase 1 trial with only 46 people, so the main goal is to find a safe dose. It is too soon to know if the combination actually improves cure rates or survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGEN DEPRIVATION THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual Pathologic Complete Response prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGEN DEPRIVATION THERAPY LOCALLY ADVANCED PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC)
RECRUITING

Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.